替罗非班不良反应分析及预防对策  

Analysis of tirofiban - induced adverse drug reactions and its preventive measures

作　　者：杨效宇[1] 胡斌[1] 王惠川[1] 陈晟[1] 薛小荣[1] YANG Xiao-yu;HU bin;WANG Hui-chuan;CHEN Sheng;XUE Xiao-rong(Department of Pharmacy,Xi'an No.4 Hospital,Xi'an 710004,China)

机构地区：[1]西安市第四医院药剂科,西安710004

出　　处：《中国新药杂志》2020年第15期1795-1800,共6页Chinese Journal of New Drugs

摘　　要：目的: 分析替罗非班相关药品不良反应( adverse drug reaction,ADR) 的发生原因及特点,为临床安全用药提供参考。方法: 对 2017 年 6 月—2019 年 6 月临床应用替罗非班抗血小板治疗患者的 612 份病例进行回顾性统计分析。结果: 共 12 例发生替罗非班相关 ADR,ADR 发生率 1. 96% ,其中男性 10 例,女性2 例,年龄 47 ~ 81 岁,65 岁以上的患者 8 例( 66. 67% ) ,用药 1 d 内发生 ADR 11 例( 91. 67% ) ,替罗非班相关ADR 以出血和血小板减少多见,造影剂肾病与该药相关的血小板减少有着相互的影响。结论: 应用替罗非班抗血小板治疗时可出现严重程度不同的 ADR,应根据患者的自身状况做到个体化用药,并加强用药期间的监测,警惕不同药物 ADR 间的相互影响,保障患者用药安全。Objective: To analyze the causes and characteristics of tirofiban-induced adverse drug reactions ( ADRs) and provide reference for clinical safe drug use. Methods: A retrospective analysis were conducted on 612 cases of antiplatelet therapy using tirofiban during June 2017 to June 2019. Results: Totally 12 patients with ADRs induced by tirofiban were collected,with an incidence rate of adverse reactions at 1. 96% ,in-cluding 10 men and 2 women,who aged 47 ~ 81,among which 8 patients ( 66. 67% ) were over 65 years old. There were 11 cases ( 91. 67% ) of adverse reactions within 1 day. ADRs induced by tirofiban were mostly hemorrhage and thrombocytopenia,and there was an interaction between contrast-induced nephropathy and tirofiban-induced thrombocytopenia. Conclusion: Different degrees of ADRs may occur in the an-tiplatelet treatment of tirofiban Individualized medicine should be performed according to the patient's own conditions,and monitoring should be strengthened during the medication,interaction between differ-ent ADRs should be paid attention to in order to protect the patient's medication safety.

关 键 词：替罗非班 不良反应 原因分析 预防对策 

分 类 号：R972[医药卫生—药品]